Diabetes is an important risk factor of coronary atherosclerosis, and it's well known that platelets of diabetic patients are hyper reactive and so resistant to common antithrombotic therapy. Moreover, in diabetic patients platelets are characterized by high turnover that is responsible of lack of protection by cardioaspirin at common dosage. The aim of our study is to asses the efficacy of different doses of aspirin in diabetic patients with acute coronary syndrome.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
Azienda Ospedaliera Universitaria Federico II
Naples, Italy
Effects of different doses of aspirin on platelet aggregation
Valuation of different doses of aspirin once or twice daily on platelet aggregation after 10 day and 30 day from the acute coronary syndrome
Time frame: 1 month
Valuation of RAC1 levels in platelets
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.